When a Drug Is in Short Supply

by Food and Drug Administration (FDA)

Infantile spasms, or West's syndrome, is a sometimes crippling and even life-threatening seizure disorder that affects about 3,000 babies a year in the United States. The only drug that helps prevent the spasms is Acthar gel (ACTH), and the drug's only manufacturer is Rhone-Poulenc Rorer Pharmaceuticals Inc.

For several months in 1996, Rhone-Poulenc stopped making Acthar because of manufacturing difficulties. A crisis resulted, with insufficient supplies to treat patients with West's syndrome and other diseases.

While the company worked with the Food and Drug Administration to fix problems in its plant, the nonprofit National Organization for Rare Disorders helped dole out the very limited supplies for emergency cases of infantile spasms and other conditions. "During the shortage, even some people with severe pain from rheumatoid arthritis couldn't get the drug in favor of babies with life-threatening West's syndrome," says NORD president Abbey Meyers.

Severe drug shortages like this one are infrequent, but a minor supply problem creating a potential shortage usually arises about once or twice a month, says FDA's drug shortage coordinator, Mark Goldberger.

Medical Necessity

Potential drug shortages are a top agency priority, according to Mark Lynch, a branch chief in FDA's division of drug manufacturing and product quality. "Shortages call for rapid communication among the key people within FDA," he says. "Those involved have to drop what they're doing and react rapidly to the crisis."

But a reduction in the drug supply doesn't always warrant this emergency status. To be defined as a high-priority drug shortage, the drug must be found to be "medically necessary." The FDA division responsible for the drug leads the determination of medical necessity. The division considers several factors, including:

• the opinion of health professionals about the drug's usefulness
• the seriousness of the medical condition
• the availability of acceptable brand-name or generic alternatives.

For example, a dangerous drug shortage occurred a few years ago when the supply of the anemia drug Desferal (deferoxamine mesylate) suddenly dropped. Desferal is the standard treatment for a fatal blood disease called Cooley's anemia. In 1995, an FDA inspection uncovered some manufacturing problems at the Swiss facility of the former Ciba-Geigy Corp., the only plant where Desferal was made, leading to a plant shutdown.

"We were fearful about the potential danger to patients based on the fact that there was no alternative source for Desferal," says Gina Cioffi, national executive director of the Cooley's Anemia Foundation. "Our patients must use this drug every day or they're taking time off their life as iron builds up in their blood."

In a drug shortage situation like the one involving Desferal, FDA takes steps to find alternative sources of the drug or control the distribution to make sure the most needy patients have access to it.

"These are acute problems that need to be addressed swiftly, with either a resolution or a short-term fix," Goldberger says. "If you've got a drug like Acthar that you need to prevent mental retardation or a drug like Desferal that you need to prevent iron overload, you can't take years. You either have to make it available quickly or figure out a substitute drug."

Increasing the Supply

The review division and office of compliance in FDA's Center for Drug Evaluation and Research work with manufacturers and third parties to find ways to keep a drug available despite various obstacles. "It's a problem-solving exercise," Lynch says. "Each situation is different, each drug is different, and the people are different each time."

The Acthar gel shortage was "different" because the drug is made from animal pituitary glands. "Because it is not synthetic, it is a difficult drug to manufacture," Goldberger says. "We worked with Rhone-Poulenc to bring the product to market while not placing an unrealistic burden on the company."

About the Author

www.fda.gov
FDA is A United States government body that oversees medical devices, including contact lenses, intraocular lenses, excimer lasers and eyedrops. In the US, these products must be approved by the FDA before they can be marketed.